Prothena Corporation plc
Prothena Corp plc (Form: 8-K, Received: 12/03/2014 06:02:57)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K  
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 2, 2014
_______________________________________________________

PROTHENA CORPORATION PUBLIC LIMITED COMPANY
(Exact Name of Registrant as Specified in its Charter)
_______________________________________________________
 
 
 
 
 
Ireland
 
001-35676
 
98-1111119
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
 
Alexandra House
The Sweepstakes, Ballsbridge
Dublin 4, Ireland
(Address of principal executive offices including Zip Code)
Registrant’s telephone number, including area code: 011-353-1-902-3519
(Former Name or Former Address, if Changed Since Last Report.)  
_______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01.
Other Events

On December 2, 2014, Dale B. Schenk, Ph.D., President and Chief Executive Officer of Prothena Corporation plc, issued a letter to colleagues and shareholders of Prothena Corporation plc, informing them of a medical condition. A copy of that letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01.
Financial Statements and Exhibits
(d)  Exhibits .
 
 
 
Exhibit No.
 
Description
99.1
 
Letter from Dale B. Schenk, Ph.D., President and Chief Executive Officer of Prothena Corporation plc.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:
December 2, 2014
PROTHENA CORPORATION PLC
 
 
 
 
 
 
 
By:
 
/s/ Tran B. Nguyen
 
 
Name:
 
Tran B. Nguyen
 
 
Title:
 
Chief Financial Officer





Exhibit 99.1




December 2, 2014


Dear Colleagues and Prothena Shareholders:

I have recently been diagnosed with pancreatic cancer. I am pleased to report that the cancer was detected early and I am doing well.

Last week, I underwent a successful resection of the tumor with a partial pancreatectomy. The cancer appeared well confined to that site. A more complete evaluation is still being undertaken, and my treatment plan will depend on that evaluation.

Although my activity will be somewhat limited while I recover from the surgery, I expect to remain actively involved in the business with the support of the outstanding management team and Board at Prothena.

I feel very good and optimistic. I believe that my personal background as a scientist is particularly helpful and beneficial in approaching this personal challenge.

I appreciate your support, and want to personally thank all our employees for the amazing work they do every day.

Sincerely,

Dale